SCHEMBL24906169

SCHEMBL24906169

CCONC(=O)c1c(Nc2ccc(C)cc2F)sc2nccc(C)c12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2K1 Q02750 9/20 0.40
MAP2K2 P36507 4/20 0.38
CISD2 Q8N5K1 1/20 0.37
ALDH1A1 P00352 1/20 0.37
HPGD P15428 1/20 0.37
ALOX15 P16050 1/20 0.37
HSD17B10 Q99714 1/20 0.37
FLT1 P17948 3/20 0.36
KDR P35968 3/20 0.36
HDAC3 O15379 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
KCNH2 Q12809 1/20 0.35
SCN5A Q14524 1/20 0.35
LIMK1 P53667 1/20 0.35
CSF1R P07333 1/20 0.35
KDM4E B2RXH2 1/20 0.34
LMNA P02545 1/20 0.34
MAPT P10636 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22045848 0.92 MAP2K1 (0.50) MAP2K1MAP2K2
SCHEMBL24906269 0.91 MAP2K1 (0.47) MAP2K1MAP2K2KCNH2
SCHEMBL24906179 0.89 FLT1 (0.38) MAP2K1MAP2K2CISD2FLT1KDR
SCHEMBL24906168 0.88 MAP2K1 (0.43) MAP2K1MAP2K2FLT1KDRHDAC3
SCHEMBL26047280 0.88 MAP2K1 (0.50) MAP2K1MAP2K2
SCHEMBL24906381 0.88 MAP2K1 (0.50) MAP2K1MAP2K2
SCHEMBL24906368 0.88 MAP2K1 (0.50) MAP2K1MAP2K2
SCHEMBL22045815 0.83 MAP2K1 (0.57) MAP2K1MAP2K2KCNH2
SCHEMBL24906176 0.82 MAP2K1 (0.40) MAP2K1MAP2K2CISD2ALDH1A1HPGD
SCHEMBL22045847 0.81 MAP2K1 (0.48) MAP2K1MAP2K2LIMK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4233834-A2 ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS NFlection Therapeutics, Inc. (US) 2023-08-30 EP disclosed
EP-4233865-A2 ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS NFlection Therapeutics, Inc. (US) 2023-08-30 EP disclosed
US-20230013227-A1 ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS NFLECTION THERAPEUTICS, INC. 2023-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230013227-A1 ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS HTR3C, NDUFA13, NDUFAF3 MAP2K1 4087/4885MAP2K2 3533/4885CISD2 2708/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.